Logo image of IUI1.DE

INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis

FRA:IUI1 - Deutsche Boerse Ag - US46120E6023 - Common Stock - Currency: EUR

589.3  +15.7 (+2.74%)

Fundamental Rating

6

Taking everything into account, IUI1 scores 6 out of 10 in our fundamental rating. IUI1 was compared to 55 industry peers in the Health Care Equipment & Supplies industry. IUI1 gets an excellent profitability rating and is at the same time showing great financial health properties. IUI1 is valued quite expensively, but it does show have an excellent growth rating. This makes IUI1 very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year IUI1 was profitable.
IUI1 had a positive operating cash flow in the past year.
In the past 5 years IUI1 has always been profitable.
In the past 5 years IUI1 always reported a positive cash flow from operatings.
IUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFIUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

1.2 Ratios

The Return On Assets of IUI1 (12.64%) is better than 92.16% of its industry peers.
With an excellent Return On Equity value of 14.39%, IUI1 belongs to the best of the industry, outperforming 86.27% of the companies in the same industry.
IUI1 has a better Return On Invested Capital (9.06%) than 80.39% of its industry peers.
IUI1 had an Average Return On Invested Capital over the past 3 years of 9.74%. This is in line with the industry average of 8.18%.
Industry RankSector Rank
ROA 12.64%
ROE 14.39%
ROIC 9.06%
ROA(3y)11.47%
ROA(5y)11.62%
ROE(3y)13.27%
ROE(5y)13.48%
ROIC(3y)9.74%
ROIC(5y)9.54%
IUI1.DE Yearly ROA, ROE, ROICIUI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 5 10 15

1.3 Margins

IUI1 has a Profit Margin of 28.51%. This is amongst the best in the industry. IUI1 outperforms 96.08% of its industry peers.
In the last couple of years the Profit Margin of IUI1 has declined.
With an excellent Operating Margin value of 26.29%, IUI1 belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
IUI1's Operating Margin has declined in the last couple of years.
IUI1 has a better Gross Margin (66.98%) than 68.63% of its industry peers.
In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
Industry RankSector Rank
OM 26.29%
PM (TTM) 28.51%
GM 66.98%
OM growth 3Y0.73%
OM growth 5Y-5.65%
PM growth 3Y1.22%
PM growth 5Y-3.58%
GM growth 3Y0.37%
GM growth 5Y-1.03%
IUI1.DE Yearly Profit, Operating, Gross MarginsIUI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 20 40 60

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IUI1 is creating some value.
Compared to 1 year ago, IUI1 has more shares outstanding
Compared to 5 years ago, IUI1 has more shares outstanding
There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IUI1.DE Yearly Shares OutstandingIUI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M
IUI1.DE Yearly Total Debt VS Total AssetsIUI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B

2.2 Solvency

An Altman-Z score of 62.57 indicates that IUI1 is not in any danger for bankruptcy at the moment.
The Altman-Z score of IUI1 (62.57) is better than 100.00% of its industry peers.
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 62.57
ROIC/WACC0.98
WACC9.24%
IUI1.DE Yearly LT Debt VS Equity VS FCFIUI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B 8B 10B

2.3 Liquidity

A Current Ratio of 4.30 indicates that IUI1 has no problem at all paying its short term obligations.
IUI1 has a better Current ratio (4.30) than 86.27% of its industry peers.
IUI1 has a Quick Ratio of 3.42. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 3.42, IUI1 belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.3
Quick Ratio 3.42
IUI1.DE Yearly Current Assets VS Current LiabilitesIUI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

More info and screens

7

3. Growth

3.1 Past

IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.84%, which is quite impressive.
Measured over the past years, IUI1 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.97% on average per year.
Looking at the last year, IUI1 shows a quite strong growth in Revenue. The Revenue has grown by 14.83% in the last year.
Measured over the past years, IUI1 shows a quite strong growth in Revenue. The Revenue has been growing by 13.85% on average per year.
EPS 1Y (TTM)25.84%
EPS 3Y19.06%
EPS 5Y8.97%
EPS Q2Q%26.03%
Revenue 1Y (TTM)14.83%
Revenue growth 3Y17.8%
Revenue growth 5Y13.85%
Sales Q2Q%16.88%

3.2 Future

Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.27% on average per year.
Based on estimates for the next years, IUI1 will show a quite strong growth in Revenue. The Revenue will grow by 14.47% on average per year.
EPS Next Y23.02%
EPS Next 2Y18.56%
EPS Next 3Y18.09%
EPS Next 5Y17.27%
Revenue Next Year14.92%
Revenue Next 2Y15.88%
Revenue Next 3Y15.86%
Revenue Next 5Y14.47%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
IUI1.DE Yearly Revenue VS EstimatesIUI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 5B 10B 15B
IUI1.DE Yearly EPS VS EstimatesIUI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 5 10 15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 91.65, which means the current valuation is very expensive for IUI1.
IUI1's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 28.64. IUI1 is valued rather expensively when compared to this.
IUI1 is valuated quite expensively with a Price/Forward Earnings ratio of 76.67.
Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than 72.55% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.51. IUI1 is valued rather expensively when compared to this.
Industry RankSector Rank
PE 91.65
Fwd PE 76.67
IUI1.DE Price Earnings VS Forward Price EarningsIUI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
IUI1's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 374.05
EV/EBITDA 82.95
IUI1.DE Per share dataIUI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
IUI1 has a very decent profitability rating, which may justify a higher PE ratio.
IUI1's earnings are expected to grow with 18.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.98
PEG (5Y)10.22
EPS Next 2Y18.56%
EPS Next 3Y18.09%

More info and screens

0

5. Dividend

5.1 Amount

IUI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTUITIVE SURGICAL INC

FRA:IUI1 (1/22/2025, 7:00:00 PM)

589.3

+15.7 (+2.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-17 2024-10-17/amc
Earnings (Next)01-23 2025-01-23/amc
Inst Owners90.55%
Inst Owner ChangeN/A
Ins Owners0.5%
Ins Owner ChangeN/A
Market Cap209.90B
Analysts80.5
Price Target562.93 (-4.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.88%
Min EPS beat(2)10.37%
Max EPS beat(2)13.38%
EPS beat(4)4
Avg EPS beat(4)8.48%
Min EPS beat(4)4.44%
Max EPS beat(4)13.38%
EPS beat(8)7
Avg EPS beat(8)4.64%
EPS beat(12)9
Avg EPS beat(12)3.16%
EPS beat(16)13
Avg EPS beat(16)6.67%
Revenue beat(2)0
Avg Revenue beat(2)-0.1%
Min Revenue beat(2)-0.14%
Max Revenue beat(2)-0.05%
Revenue beat(4)1
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-0.76%
Max Revenue beat(4)0.12%
Revenue beat(8)2
Avg Revenue beat(8)-0.46%
Revenue beat(12)4
Avg Revenue beat(12)-0.43%
Revenue beat(16)7
Avg Revenue beat(16)1.66%
PT rev (1m)6.95%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.55%
EPS NY rev (1m)0%
EPS NY rev (3m)3.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.31%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)0.62%
Valuation
Industry RankSector Rank
PE 91.65
Fwd PE 76.67
P/S 27.86
P/FCF 374.05
P/OCF 120.39
P/B 14.07
P/tB 14.41
EV/EBITDA 82.95
EPS(TTM)6.43
EY1.09%
EPS(NY)7.69
Fwd EY1.3%
FCF(TTM)1.58
FCFY0.27%
OCF(TTM)4.89
OCFY0.83%
SpS21.15
BVpS41.9
TBVpS40.89
PEG (NY)3.98
PEG (5Y)10.22
Profitability
Industry RankSector Rank
ROA 12.64%
ROE 14.39%
ROCE 12.87%
ROIC 9.06%
ROICexc 12.45%
ROICexgc 12.86%
OM 26.29%
PM (TTM) 28.51%
GM 66.98%
FCFM 7.45%
ROA(3y)11.47%
ROA(5y)11.62%
ROE(3y)13.27%
ROE(5y)13.48%
ROIC(3y)9.74%
ROIC(5y)9.54%
ROICexc(3y)15.43%
ROICexc(5y)15.82%
ROICexgc(3y)16.26%
ROICexgc(5y)16.89%
ROCE(3y)13.84%
ROCE(5y)13.55%
ROICexcg growth 3Y-1.89%
ROICexcg growth 5Y-8.22%
ROICexc growth 3Y-0.57%
ROICexc growth 5Y-7.6%
OM growth 3Y0.73%
OM growth 5Y-5.65%
PM growth 3Y1.22%
PM growth 5Y-3.58%
GM growth 3Y0.37%
GM growth 5Y-1.03%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 247.98%
Cap/Sales 15.69%
Interest Coverage 250
Cash Conversion 70.95%
Profit Quality 26.12%
Current Ratio 4.3
Quick Ratio 3.42
Altman-Z 62.57
F-Score5
WACC9.24%
ROIC/WACC0.98
Cap/Depr(3y)158.69%
Cap/Depr(5y)157.89%
Cap/Sales(3y)9.9%
Cap/Sales(5y)9.4%
Profit Quality(3y)72%
Profit Quality(5y)81.76%
High Growth Momentum
Growth
EPS 1Y (TTM)25.84%
EPS 3Y19.06%
EPS 5Y8.97%
EPS Q2Q%26.03%
EPS Next Y23.02%
EPS Next 2Y18.56%
EPS Next 3Y18.09%
EPS Next 5Y17.27%
Revenue 1Y (TTM)14.83%
Revenue growth 3Y17.8%
Revenue growth 5Y13.85%
Sales Q2Q%16.88%
Revenue Next Year14.92%
Revenue Next 2Y15.88%
Revenue Next 3Y15.86%
Revenue Next 5Y14.47%
EBIT growth 1Y21.07%
EBIT growth 3Y18.66%
EBIT growth 5Y7.42%
EBIT Next Year41.2%
EBIT Next 3Y24.93%
EBIT Next 5Y22.48%
FCF growth 1Y-45.49%
FCF growth 3Y-13.13%
FCF growth 5Y-5.26%
OCF growth 1Y12.35%
OCF growth 3Y6.9%
OCF growth 5Y9.17%